An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients |
| |
Authors: | La Verde Nicla Garassino Marina Bareggi Claudia Sburlati Paola Borgonovo Karen Dimaiuta Mariastella Mantica Cristina Perrone Silvia Torri Valter Farina Gabriella |
| |
Affiliation: | Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy. nicla.laverde@fbf.milano.it |
| |
Abstract: | AIMS AND BACKGROUND: The purpose of the study was to evaluate the outcome of metastatic colorectal cancer patients treated, as first line, with 5-fluorouracil bolus/leucovorin + oxaliplatin, in terms of response, progression-free and overall survival. MATERIALS AND METHODS: A retrospective cohort of consecutive metastatic colorectal cancer patients, treated from 2003 to 2006, was identified and analyzed. All patients, without a central venous device, were treated with oxaliplatin + 5-fluorouracil and leucovorin. RESULTS: Twenty-five metastatic colorectal cancer patients were treated. No 3-4 grade toxicity was observed. Five of 23 patients achieved a partial response: one of them resulted in a complete response after radiofrequency and another one after surgery. Fifteen of 23 patients had stable disease (one underwent radical surgery after chemotherapy, obtaining a complete remission) and 3 had progressive disease. Median progression-free survival was 7.2 months, and median overall survival was 30 months. CONCLUSIONS: Based on this case-series study, the regimen seems to offer a good control of disease (86.9%) and can be considered as an alternative choice for patients who cannot receive continuous infusion. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|